Best Practice Database Provides Key Findings for Biopharma Product Launch ...( CHAPEL HILL N.C. Nov. 13 /- Bio-P...),Health

CHAPEL HILL, N.C., Nov. 13 /PRNewswire/ -- Bio-Pharma executives are increasingly finding value in the research products and services offered by Best Practices, LLC and in particular in use of the on-demand benchmark repository known as the Best Practice Database ( http://www.BestPracticeDatabase.com ). Although documents from the database may be accessed and downloaded individually, many commercial and operations leaders have come to find outstanding value in membership to the database which not only provides full access to all content as needed, but also includes services such as new research alerts, invitations to participate in topical new studies and ongoing advisory services to address research needs.

As biopharmaceutical companies continue to bring new therapies to market, considerable efforts are placed on strategy and execution from development through launch, while post-launch evaluations largely focus on revenue growth and little else. In a continuing effort to support product launch excellence, a recent study was conducted by Best Practices, LLC reviewing launch evaluation with insights available in the newly published report, "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success." This research initiative explored excellence in launch evaluation yielding key findings into continuous improvement strategies, plans and practices for both current and future landscapes across the biopharmaceutical industry.

To view the study abstract or complimentary summary of the full report "Pharmaceutical Product Launch Evaluation Excellence: Processes & Measures to Evaluate Launch Success," click on the following link http://www3.best-in-class.com/dr338.htm .

In a benchmarking study that included such influential companies as Abbott, GlaxoSmithKline, Novo Nordisk, R
'/>"/>